Bio-Path Holdings, Inc. (BPTH) Stock Forecast
BPTH analyst forecast
as of October 21, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $2.00 average of analyst targets
- Upside to target
- +666,566.7% from the latest close
- Next earnings
- —
- 52-week range
- $0.00 – $0.00
BPTH analyst ratings
1 analystsNumber of analysts at each rating.
BPTH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BPTH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$1.42 | −$1.42 | −$1.42 | −$1.59 | +10.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BPTH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
BPTH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BPTH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$1.48 | −$1.28 | −$1.28 | −$1.28 | −$1.42 | −4.1% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BPTH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BPTH beat in 4 of 12.
What analysts expect from BPTH
1 analysts cover Bio-Path; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.00, 666,566.7% above the latest close of $0.00. For 2026 the average estimate is −$1.42 per share. Bio-Path beat the EPS estimate in 4 of the last 12 quarters.
Related: BPTH income statement, BPTH key metrics, BPTH chart. See the BPTH stock overview for the latest quote and news.
BPTH forecast FAQ
What is Bio-Path's price target?
The average analyst price target for Bio-Path is $2.00, 666,566.7% above the latest close of $0.00.
Is Bio-Path a buy, hold or sell?
Of 1 analysts covering Bio-Path, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
Does Bio-Path usually beat earnings estimates?
Bio-Path reported EPS at or above the analyst estimate in 4 of the last 12 quarters.